Drug-Eluting Balloon Versus Standard Balloon Angioplasty for Infrapopliteal Arterial Revascularization in Critical Limb Ischemia 12-Month Results From the IN.PACT DEEP Randomized Trial by Zeller, Thomas et al.
J O U R N A L O F T H E A M E R I C A N C O L L E G E O F C A R D I O L O G Y V O L . 6 4 , N O . 1 5 , 2 0 1 4
ª 2 0 1 4 B Y T H E AM E R I C A N C O L L E G E O F C A R D I O L O G Y F O U N D A T I O N I S S N 0 7 3 5 - 1 0 9 7 / $ 3 6 . 0 0
P U B L I S H E D B Y E L S E V I E R I N C . h t t p : / / d x . d o i . o r g / 1 0 . 1 0 1 6 / j . j a c c . 2 0 1 4 . 0 6 . 1 1 9 8Drug-Eluting Balloon Versus
Standard Balloon Angioplasty for
Infrapopliteal Arterial Revascularization
in Critical Limb Ischemia
12-Month Results From the IN.PACT DEEP Randomized TrialThomas Zeller, MD,* Iris Baumgartner, MD,y Dierk Scheinert, MD,z Marianne Brodmann, MD,x Marc Bosiers, MD,k
Antonio Micari, MD, PHD,{ Patrick Peeters, MD, PHD,# Frank Vermassen, MD, PHD,** Mario Landini, MS,yy
David B. Snead, PHD,yy K. Craig Kent, MD,zz Krishna J. Rocha-Singh, MD,xx IN.PACT DEEP Trial InvestigatorsABSTRACTFro
dio
Ho
Su
#D
Gh
ge
Joh
fee
Bo
Dr
All
Lis
Yo
MaBACKGROUND Drug-eluting balloons (DEB) may reduce infrapopliteal restenosis and reintervention rates versus
percutaneous transluminal angioplasty (PTA) and improve wound healing/limb preservation.
OBJECTIVES The goal of this clinical trial was to assess the efﬁcacy and safety of IN.PACT Amphirion drug-eluting bal-
loons (IA-DEB) compared to PTA for infrapopliteal arterial revascularization in patients with critical limb ischemia (CLI).
METHODS Within aprospective,multicenter, randomized, controlled trialwith independent clinical event adjudicationand
angiographic andwound core laboratories 358 CLI patients were randomized 2:1 to IA-DEB or PTA. The 2 coprimary efﬁcacy
endpoints through 12 months were clinically driven target lesion revascularization (CD-TLR) and late lumen loss (LLL). The
primary safety endpoint through 6 months was a composite of all-cause mortality, major amputation, and CD-TLR.
RESULTS Clinical characteristics were similar between the 2 groups. Signiﬁcant baseline differences between the IA-DEB
and PTA arms includedmean lesion length (10.2 cmvs. 12.9 cm; p¼0.002), impaired inﬂow (40.7% vs. 28.8%; p¼0.035),
and previous target limb revascularization (32.2% vs. 21.8%; p ¼ 0.047). Primary efﬁcacy results of IA-DEB versus PTA
were CD-TLR of 9.2% versus 13.1% (p ¼ 0.291) and LLL of 0.61  0.78 mm versus 0.62  0.78 mm (p ¼ 0.950). Primary
safety endpoints were 17.7% versus 15.8% (p ¼ 0.021) and met the noninferiority hypothesis. A safety signal driven by
major amputations through 12 months was observed in the IA-DEB arm versus the PTA arm (8.8% vs. 3.6%; p ¼ 0.080).
CONCLUSIONS In patients with CLI, IA-DEB had comparable efﬁcacy to PTA. While primary safety was met, there was a
trend towards an increased major amputation rate through 12 months compared to PTA. (Study of IN.PACT Amphirion
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1569AB BR E V I A T I O N S
AND ACRONYM S
CD-TLR = clinically driven
target lesion revascularization
CLI = critical limb ischemia
DEB = drug-eluting balloon
IA-DEB = IN.PACT Amphirion
drug-eluting balloon
LLL = late lumen loss
PTA = percutaneous
transluminal angioplasty
TLR = target lesion
revascularizationB alloon angioplasty (percutaneous translumi-nal angioplasty [PTA]) of infrapopliteal ar-teries in critical limb ischemia (CLI) is a
common, established practice worldwide. The devel-
opment of long, low-proﬁle balloons has contributed
to their widespread adoption in the treatment of
this complex disease process, which is characterized
by multilevel, multivessel, long-segment atheroscle-
rosis (1–6). However, despite suboptimal long-term
patency rates and poor correlation between primary
patency and limb preservation (7), PTA is an accepted
“ﬁrst-line” therapy to re-establish direct blood ﬂow to
the foot in patients with suitable anatomy where pro-
cedural success is favorably balanced by relatively
minimal risk. With low procedure-related complica-
tion rates, infrapopliteal PTA frequency has increased
and, when combined with an adequate wound care
program, is associated with acceptable near-term
limb preservation rates reported in small single-
center experiences and registries in CLI patient co-
horts. However, reintervention to re-establish limb
perfusion after clinical restenosis is associated with
increased morbidity and mortality rates in this sick
patient population (8,9) and poorer surgical out-
comes when repeated revascularization procedures
ultimately fail (10,11). Durable infrapopliteal vessel
patency may promote faster, more sustained, com-
plete wound healing (12) and limb preservation, and
is a desired revascularization goal.SEE PAGE 1577Paclitaxel drug-eluting balloons (DEBs) have
recently been introduced to reduce vessel restenosis
and, potentially, to facilitate sustained wound
healing and improve limb preservation. Two single-
center, self-adjudicated studies, the ﬁrst retrospec-
tive (13) and the second randomized (14), suggested
that use of the paclitaxel-eluting IN.PACT Amphirion
DEB (IA-DEB) may reduce infrapopliteal vessel
restenosis and reintervention rates. Therefore, we
sought to conﬁrm these preliminary ﬁndings in this
ﬁrst large, multicenter, randomized, controlled trial
of IA-DEB and PTA in CLI patients.
METHODS
The IN.PACT DEEP (RandomIzed AmPhirion DEEP
DEB vs StAndard PTA for the treatment of below the
knee CriTical limb ischemia) trial (15) rationale and
design, statistical hypothesis/methodology primary
and secondary endpoints, and inclusion and exclu-
sion criteria were previously published (16). The
IN.PACT DEEP trial is a prospective, multicenter,
patient-blinded randomized controlled trial ofIA-DEB (Medtronic, Santa Rosa, California)
versus PTA for the treatment of infrapop-
liteal arterial disease in patients presenting
with CLI.
PRIMARY ENDPOINTS. The study hypothesis
of superior efﬁcacy of IA-DEB versus PTA
(primary efﬁcacy endpoint) was on the basis of
2 coprimary endpoints assessed through 12
months: clinically driven target lesion revas-
cularization (CD-TLR) and late lumen loss
(LLL). CD-TLR was evaluated in the entire
patient population, while LLL was evaluated
in a subcohort of patients meeting speciﬁc
eligibility criteria (including lesion length #10 cm)
and consented for 12-month angiographic follow-up.
The primary safety endpoint is a composite of
all-cause death, major amputation, and CD-TLR
revascularization rate assessed through 6 months
and is on the basis of a noninferiority hypothesis with a
10% margin.
DEFINITIONS. CD-TLR is deﬁned as any TLR associ-
ated with deterioration of Rutherford category and/or
increasing size of pre-existing wounds and/or occur-
rence of new wounds as adjudicated by the wound
core laboratory.
Device success is deﬁned as exact device deploy-
ment according to the instructions for use as docu-
mented in at least 2 different imaging projections.
Technical success is deﬁned as successful vascular
access and completion of the endovascular procedure
and immediate morphological success with endovas-
cular procedure with #50% residual diameter reduc-
tion of the treated lesion on completion angiography.
Procedural success is deﬁned as the combination of
technical success, device success, and absence of
procedural complications. Procedural complications
included abrupt closure, distal embolization, perfo-
ration, aneurysm, vasospasm, thrombus, and recoil as
adjudicated by the Angiographic Core Lab (SynvaCor,
Springﬁeld, Illinois). Patient follow-up through 5
years is ongoing; the primary safety and efﬁcacy
endpoints were reached at 6 and 12 months, respec-
tively. All patients with iliac or femoropopliteal
inﬂow lesions were treated accordingly in the setting
of the index procedure. Failure to obtain <30% re-
sidual stenosis post-treatment constituted an exclu-
sion criterion.
The trial was independently adjudicated, super-
vised, and monitored, and included angiographic,
and wound core laboratories (16). A clinical event
committee, data safety monitoring board, and
external data monitoring with 100% source data
veriﬁcation were also included in the trial protocol.
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1570An electronic reader (SilhouetteMobile, Aranz
Medical Limited, Auckland, New Zealand), consisting
of a laser-assisted camera, was used to obtain
accurate, operator-independent wound areas and
depths at baseline and at follow-up; all data and
images were analyzed by the Wound Core Lab (Syn-
vaCor, Springﬁeld, Illinois). Both wound and angio-
graphic core laboratories were blinded to the assigned
treatment. The IN.PACT DEEP trial was conducted
in compliance with the principles of the Declaration
of Helsinki, ISO 14155, and Good Clinical Practices
guidelines. Written informed consent was obtained
from all enrolled patients and ethics committees of
all investigational sites approved the trial protocol.
Statistical methods and analysis were performed by
the study sponsor and were previously reported in
detail (16). All patients with iliac or femoropopliteal
inﬂow lesions were treated accordingly during the
index procedure. Failure to obtain <30% residual
stenosis post-treatment constituted an exclusion
criterion.
STATISTICAL ANALYSIS. The total sample size for
the IN.PACT DEEP trial was calculated at 357 subjects,
which fully powers the coprimary endpoints of LLL
(80%) for superiority and the primary composite
safety endpoint (80%) on the basis of initial estimates
of event rates and effect sizes of the 2 arms for non-
inferiority, IA-DEB and PTA randomized 2:1. The358 enrolled
358 randomized
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DEB ¼ drug-eluting balloon; ITT ¼ intention to treat;
transluminal angioplasty.primary coefﬁcacy endpoint of 12-month TLR was
powered to 65% with the indicated sample size.
The ﬁrst primary efﬁcacy endpoint was LLL,
assessed at 12 months or at the time of TLR. The
second primary efﬁcacy endpoint was incidence of
CD-TLR assessed through 12 months. Each was tested
for superiority in comparison of the randomized
groups. All analyses were on the basis of the
intention-to-treat principle. Statistical analyses were
performed using IBM SPSS Software. An interim
analysis was performed on the ﬁrst 150 subjects,
incurring a 0.2% adjustment to the alpha level.
PRIMARY EFFICACY ENDPOINT: ANGIOGRAPHIC
COHORT. The statistical hypothesis of superiority for
LLL at 12 months was assessed using a 2-sample
Student t test of IA-DEB versus PTA, with a 4.8%
2-sided alpha.
PRIMARY EFFICACY ENDPOINT: CLINICAL COHORT.
For the efﬁcacy endpoint of 12-month TLR, the sta-
tistical hypothesis was tested using Fisher’s exact test
for proportions of IA-DEB versus PTA with 4.8%
2-sided alpha.
PRIMARY SAFETY ENDPOINT. The primary safety
endpoint for the trial was a composite of all-cause
death, major amputation, and CD-TLR at 6 months
tested for noninferiority with a 10% margin and 4.8%
1-sided alpha.
RESULTS
From September 2009 to July 2012, a total of 358 pa-
tients were enrolled across 13 European sites (Online
Appendix) and randomized 2:1 to IA-DEB versus PTA
with all subjects evaluated in the clinical cohort and
167 of these subjects studied in the angiographic
cohort. Patient distribution within the 2 cohorts and
through 12 months is described in the patient ﬂow
diagram (Figure 1).
KEY CLINICAL CHARACTERISTICS. Patients in the
IA-DEB and PTA arms presented predominantly with
Rutherford Category 5 (84.1% and 77.3%, respec-
tively) when compared with Rutherford Category 4
(14.2% and 17.6%, respectively) and 6 (1.7% and 4.2%,
respectively). The salient demographic features of the
2 cohorts are detailed in Table 1 and reﬂect the chal-
lenging nature of CLI patients: 75.7% and 68.9% were
diabetics, 8.6% and 12.5% had renal insufﬁciency
(glomerular ﬁltration rate <30 ml/min), and 6.7% and
3.4% were conﬁned to bed in the IA-DEB and PTA
arms, respectively. None of the previously mentioned
characteristics differ signiﬁcantly between the 2
arms. Prior TLR was signiﬁcantly higher in the IA-DEB
(32.2%) versus the PTA (21.8%) arm (p ¼ 0.047).
TABLE 1 Baseline Patient Characteristics (ITT Population)
IA-DEB PTA p Value
Age, yrs 73.3  8.2 71.7  9.9 0.106
Male 76.2 (182/239) 70.6 (84/119) 0.304
Diabetes 75.7 (181/239) 68.9 (82/119) 0.204
Hypertension 89.5 (214/239) 89.1 (106/119) 1.000
Hyperlipidemia 73.2 (175/239) 67.2 (80/119) 0.265
Smoker 15.1 (36/239) 13.4 (16/119) 0.752
Renal insufﬁciency (GFR <30 ml/min) 8.6 (20/233) 12.5 (14/112) 0.254
History of PAD 100 (239/239) 100 (119/119) NA
Rutherford class 0.581
3 0.0 (0/239) 0.8 (1/119)
4 14.2 (34/239) 17.6 (21/119)
5 84.1 (201/239) 77.3 (92/119)
6 1.7 (4/239) 4.2 (5/119)
ABI (all patients) 0.75  0.40 0.81  0.44 0.264
ABI ($1.3)* 0.63  0.248 0.62  0.228 0.851
TBI 0.32  0.20 0.46  0.42 0.178
TcPO2 18.6  17.5 15.8  13.6 0.475
CRP 12.0  31.1 13.3  35.4 0.750
BMI, kg/m2 27.4  4.9 27.1  4.9 0.620
Previous coronary revascularization 32.6 (78/239) 27.7 (33/119) 0.396
Previous carotid revascularization 5.0 (12/239) 2.5 (3/119) 0.402
Previous target limb revascularization 32.2 (77/239) 21.8 (26/119) 0.047
Values are mean  SD or % (n/N). *Calculated by excluding ankle brachial index (ABI) $ 1.3 (25 patients in the
DEB arm and 19 in the percutaneous transluminal angioplasty [PTA] arm).
BMI ¼ body mass index; CRP ¼ C-reactive protein; GFR ¼ glomerular ﬁltration rate; IA-DEB ¼ IN.PACT
Amphirion drug-eluting balloon; ITT ¼ intention to treat; PAD ¼ peripheral artery disease; TBI ¼ toe brachial
index; TcPO2 ¼ transcutaneous oximetry.
TABLE 2 Baseline Wound Characteristics (ITT Population)
IA-DEB PTA p Value
Wounds per patient 1.4  0.7 1.5  0.8 0.405
Wound location
None 14.3 (34/237) 17.9 (21/117)
Calf 6.8 (16/237) 10.3 (12/117)
Ankle 8.4 (20/237) 6.0 (7/117) 0.218
Foot 21.5 (51/237) 27.4 (32/117)
Toe 48.9 (116/237) 38.5 (45/117)
Heel 8.4 (14/167) 16.3 (14/86)
Wound care provider
Self-care 23.5 (56/238) 29.4 (35/119)
Physician’s ofﬁce 22.7 (54/238) 24.4 (29/119) 0.162
Wound care center 39.5 (94/238) 27.7 (33/119)
N/A 14.3 (34/238) 18.5 (22/119)
Wound care
Surgical debridement 5.4 (11/205) 6.1 (6/98) 0.793
Dry dressing 67.6 (138/204) 68.0 (66/97) 1.000
Wet dressing 28.8 (59/205) 24.5 (24/98) 0.492
Maggots 0.5 (1/205) 0.0 (0/98) 1.000
Vacuum 1.0 (2/205) 0.0 (0/98) 1.000
Others 9.3 (19/205) 9.2 (9/98) 1.000
Wound area, cm2 4.79  10.96 6.91  14.53 0.296
Wound depth, mm 0.84  1.27 1.77  3.81 0.040
Values are mean  SD or % (n/N).
Abbreviations as in Table 1.
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1571KEY ANGIOGRAPHIC CHARACTERISTICS. Impaired
inﬂow was signiﬁcantly higher in the IA-DEB arm
(40.7%) versus the PTA (28.8%) arm (p¼ 0.035). Target
lesions were signiﬁcantly longer (12.9  9.5 cm vs. 10.2
 9.1 cm) in the PTA arm versus the IA-DEB arm (p ¼
0.002). Total occlusions were 38.6% in the IA-DEB arm
and 45.9% in the PTA arm (p ¼ 0.114). An incomplete
pedal loop occurred frequently, with at least 1 portion
of the posterior-plantar, the plantar arch, or the ante-
rior dorsalis path being either occluded or stenotic in
78.2% of IA-DEB arm patients and 70.6% of PTA arm
patients (p¼ 0.118). Conversely, a complete pedal loop
was rarely present in IA-DEB (5.4%) and PTA patients
(7.6%; p¼ 0.485), while complete pedal loop occlusion
was present in 7.1% of IA-DEB patients and 11.8% of
PTA patients (p ¼ 0.163). Mean lesion lengths in the
167-patient angiography cohort were 5.91  4.17 cm
and 7.97  7.46 cm (p ¼ 0.060) with total occlusion
present in 31.6% and 32.7% (p ¼ 1.000) of the IA-DEB
versus PTA treatment arms, respectively. The per-
centages of patients evaluable for angiographic core
laboratory analysis were 52.6% and 52.7% in the
IA-DEB and PTA arms, respectively.
KEY WOUND CHARACTERISTICS. Ischemic wound
size and distribution of the treated limbs are
described in Table 2. Wound location in the IA-DEB
and PTA arms included the foot in 79.3% and 79.1%
(p ¼ 0.818); toe wounds occurred in 64.9% and
63.1% (p ¼ 0.799) and heel wounds in 8.0% and 15.5%
(p ¼ 0.072), respectively. By core laboratory evalua-
tion, the wound area was 4.8  11.0 cm2 and 6.9 
14.5 cm2 (p ¼ 0.296) and wound depth was 0.8 
1.3 mm and 1.8  3.8 mm in the IA-DEB arm versus the
PTA arm, respectively (p ¼ 0.040) documenting
signiﬁcantly deeper wounds in the PTA arm. Profes-
sional wound care was received in 62.2% of IA-DEB
and 52.1% of PTA patients (p ¼ 0.087), whereas
23.5% of IA-DEB patients and 29.4% of PTA patients
received self–wound care (p ¼ 0.248).
KEY PROCEDURAL CHARACTERISTICS. Pre-dilation
of the target lesion was performed in 90.5% of
patients in the IA-DEB arm and 36.0% of patients in
the PTA arm (p < 0.001). Direct revascularization to
the wound-related artery was obtained in 35.6% of
patients in the IA-DEB arm and 43.7% of patients in
the PTA arm (p ¼ 0.166).
Procedural complications did not differ signiﬁ-
cantly when individually assessed; the aggregate
incidence was signiﬁcantly higher in the IA-DEB arm
(9.7%) versus the PTA (3.4%) arm (p ¼ 0.035). Freedom
from post-procedural dissection was higher in the IA-
DEB (87.7%) versus the PTA (80.8%) arm (p ¼ 0.045)
and was primarily mild and non–ﬂow limiting; bailout
TABLE 4 12-Month E
Late lumen loss,* mm
Binary restenosis*
Occlusion rate
Longitudinal restenosis
Clinically driven TLR (A
Clinically driven TLR (a
Values are mean  SD or %
treated lesion length (angi
AFS ¼ amputation-free s
TABLE 3 Baseline Angiographic and Procedural Characteristics (ITT Population)
IA-DEB PTA p Value
Lesion length, cm 10.15  9.10 12.86  9.46 0.002
Lesion length in angiography cohort, cm 5.91  4.17 7.97  7.46 0.060
Reference vessel diameter, mm 2.46  0.69 2.41  0.56 0.304
Total occlusions 38.6 (135/350) 45.9 (83/181) 0.114
Restenotic lesions 6.7 (24/359) 3.7 (7/189) 0.176
Severe calcium 13.7 (48/350) 10.5 (19/181) 0.336
% Diameter stenosis (pre-procedure) 83.9  16.9 86.6  15.7 0.078
% Diameter stenosis (post-procedure) 25.6  14.8 28.0  13.0 0.066
Pedal-loop 0.356
Complete 5.4 (13/239) 7.6 (9/119)
Incomplete 78.2 (187/239) 70.6 (84/119)
No pedal-loop 7.1 (17/239) 11.8 (14/119)
N/A 9.2 (22/239) 10.1 (12/119)
Pre-dilation 90.5 (325/359) 36.0 (68/189) <0.001
Inﬂation time, s* 166.0  138.4 137.7  111.3 0.010
Maximum inﬂation pressure, atm 9.5  2.4 10.3  4.6 0.010
Post-dilation 10.3 (37/359) 8.5 (16/189) 0.488
Stenting 3.9 (14/359) 2.6 (5/189) 0.446
Procedural complications† 9.7 (23/238) 3.4 (4/119) 0.035
Distal embolization 2.8 (9/319) 0.6 (1/169) 0.176
Post-procedural dissections 12.3 (42/342) 19.2 (34/177) 0.046
Device success‡ 98.0 (348/355) 96.3 (182/189) 0.224
Technical success§ 93.2 (331/355) 88.4 (167/189) 0.051
Procedural successk 79.7 (177/222) 78.2 (86/110) 0.744
Values are mean  SD or % (n/N). *Total inﬂation time of treatment device per device. †Excluding post-
procedure dissections. ‡Technical success ¼ successful vascular access, completion of the endovascular proce-
dure, and immediate morphological success with #50% residual diameter stenosis by angiography. §Device
success ¼ exact deployment of the device according to the instructions for use, as documented with suitable
imaging modalities, and in the case of digital subtraction angiography in at least 2 different imaging projections.
kProcedural success ¼ combination of technical success, device success, and absence of procedural
complications.
Abbreviations as in Table 1.
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1572stenting was performed in 2.3% of IA-DEB patients and
2.8% of PTA patients (p¼0.771). Baseline angiographic
and procedural characteristics are described in Table 3.
Site-reported Device Success was 98.0% for the IA-DEB
arm and 96.3% for the PTA arm (p ¼ 0.224). Site re-
ported Technical Success was 90.8% for the IA-DEB
arm and 91.2% for the PTA arm (p ¼ 0.885). Proce-
dural Success was 81.4% for the IA-DEB arm and 79.1%
for the PTA arm (p ¼ 0.609).fﬁcacy Endpoints
IA-DEB PTA p Value
0.605  0.775 0.616  0.781 0.950
41.0 (25/61) 35.5 (11/31) 0.609
11.5 (7/61) 16.1 (5/31) 0.531
† 62.7  56.2 93.2  60.8 0.167
FS subjects) 9.2 (18/196) 13.1 (14/107) 0.291
ll ITT subjects) 11.9 (27/226) 13.5 (15/111) 0.682
(n/N). *Angiographic cohort (core lab analyzed). †Mean % of stenosis length versus
ographic cohort).
urvival; TLR ¼ target lesion revascularization; other abbreviations as in Table 1.PRIMARY EFFICACY RESULTS. The 12-month CD-
TLR rate was 9.2% in the IA-DEB arm and 13.1% in
the PTA arm (p ¼ 0.291) when assessed in the
protocol-speciﬁed amputation-free surviving popu-
lation and 11.9% in the PTA arm and 13.5% in the PTA
arm (p ¼ 0.682) when assessed in the entire 358-
patient population with respective cumulative TLR
rates of 15.5% and 20.2% (p ¼ 0.2665). In the 167-
patient angiography cohort, there were no differ-
ences (p ¼ 0.950) between the IA-DEB arm (0.61 
0.78 mm) and the PTA arm (0.62  0.78 mm) in the
12-month angiographic core laboratory assessments
of LLL. Furthermore, angiographic core laboratory
secondary efﬁcacy analysis at 12-month follow-up
showed no differences in binary ($50% diameter
stenosis) restenosis rates (41.0% vs. 35.5%; p ¼ 0.609)
and reocclusion rates (11.5% vs. 16.1%; p ¼ 0.531) of
the IA-DEB versus the PTA arm, respectively.
There were no reported differences in longitudinal
restenosis, calculated as the mean ratio (%)
between the length of the restenotic (<50% diameter
stenosis) lesion and the initial lesion length,
between the IA-DEB (99.7  120.2%) and the PTA
(88.3  40.5%) arms (p ¼ 0.774). The 12-month pri-
mary and secondary efﬁcacy results are described in
Table 4.
PRIMARY SAFETY RESULTS. The composite of all-
cause death, major amputation, and CD-TLR rates
through 6 months were 17.7% in the IA-DEB arm and
15.8% in the PTA arm (p ¼ 0.021 for noninferiority).
A safety signal driven by major amputation at
12-months was observed, with respective rates of 8.8%
and 3.6% (p ¼ 0.080) in the IA-DEB arm and the PTA
arm (Figure 2). Major amputation-free survival at 12
months was 81.1% and 89.2% (p ¼ 0.057), respectively,
in the IA-DEB and PTA arms. All-cause mortality rates
were 10.1% for IA-DEB and 8.1% for PTA (p¼0.551). The
combined endpoint, including all-cause death/major
or minor amputation rate, was 35.2% for IA-DEB and
25.2% for PTA (p ¼ 0.064). The overall complication
rate, a composite of core laboratory-adjudicated inci-
dence of vasospasm, abrupt closure, vessel recoil,
thrombus, and perforation, was higher in the IA-DEB
arm versus the PTA arm (9.7% vs. 3.4%; p ¼ 0.035);
however, these complications were successfully
managed and were not associated with a higher inci-
dence of distal embolization or need for provisional
stent deployment. Wound healing was reported in
73.8% of IA-DEB patients versus 76.9% of the PTA pa-
tients (p¼0.579). Primary and secondary safety results
are described in Table 5.
In the IA-DEB and PTA arms, 52.6% and 52.7%
of patients were respectively evaluable by the
angiographic core laboratory and 40.4% and 53.3%
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FIGURE 2 Freedom from Major Amputation (ITT population)
Survival distribution function estimate over 360-day period for subjects with major
amputation for Rutherford Classes 4, 5, and 6. Abbreviations as in Figure 1.
TABLE 5 Primary and Secondary Safety Endpoints
IA-DEB PTA p Value
6-month primary safety endpoint 17.7 (41/232) 15.8 (18/114) 0.021*
12-month major amputation 8.8 (20/227) 3.6 (4/111) 0.080
12-month all-cause mortality 10.1 (23/227) 8.1 (9/111) 0.551
12-month death and amputations† 35.2 (80/227) 25.2 (28/111) 0.064
12-month death, major amputation or
clinically driven TLR‡
26.9 (61/227) 23.4 (26/111) 0.496
Amputation-free survival 81.1 (184/227) 89.2 (99/111) 0.057
Values are % (n/N). *For noninferiority. †Death from any cause, major or minor amputation, of target limb (major
adverse event per protocol). ‡Death from any cause, target limb major amputation, and clinically driven TLR.
Abbreviations as in Tables 1 and 4.
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Most qualifying angiogram losses were the result of
subject death, major amputation of the target limb,
subject withdrawal, or patient refusal of the
angiogram.
SUBGROUP AND MULTIVARIATE ANALYSIS. Rutherford
Category indicated no differences in the 6-month
primary safety endpoint, the 12-month major ampu-
tation or mortality. There were also no differences in
the primary efﬁcacy endpoints (Table 6). Additional
post hoc subanalyses, including impact of interven-
tion on the wound related artery (direct vs. indirect)
or pedal loop status, did not reveal any beneﬁcial
subgroups. By post hoc multivariate analysis,
conﬁnement to bed with a hazard rate of 3.9 was the
only signiﬁcant factor identiﬁed as affecting major
amputations within 1 year.
DISCUSSION
The IN.PACT DEEP trial is a randomized, indepen-
dently adjudicated post-market trial designed to
assess the efﬁcacy and safety of IA-DEB within the CLI
population. The trial failed to meet its primary efﬁcacy
endpoint of IA-DEB superiority compared to PTA. All
lesion-speciﬁc primary and secondary endpoints
showed insigniﬁcant differences between the 2 study
arms. Such similar angiographic results were com-
bined with a lower major amputation rate in the PTA
arm, despite signiﬁcantly longer lesions and deeper
ulcers in the control arm. This observation further
conﬁrms the lack of treatment effect of the study de-
vice in reducing restenosis and supports the hypoth-
esis of multiple concomitant factors in the complex
chain of CLI therapy, which may have contributed to
this difference in clinical outcome. Although the pri-
mary safety endpoint was statistically met through a
pre-speciﬁed noninferiority analysis, secondary safety
endpoints including major amputation rate, death,
amputations, and amputation-free survival trended
against the IA-DEB treatment arm. The observed
absence of efﬁcacy superiority compared to PTA and
the safety signal resulted in the sponsor’s decision to
withdraw the IA-DEB device from the market.
CLI patients are at risk for restenosis and compli-
cations arising from progression of the atherosclerotic
process. The PTA arm had more favorable efﬁcacy and
safety outcomes compared to historical trials; the
extraordinarily low 35% 12-month binary restenosis
rate and major amputation rate of 3.6% in the PTA
arm compare very favorably to previously published
data in similar CLI populations treated with PTA
alone (17–20). While the IN.PACT DEEP trial may set a
new benchmark with standard PTA for the treatmentof CLI patients due to the observed extremely low
reintervention and amputation rates, alternative
therapies, such as drug-eluting stents for short
lesions or bypass for longer lesions, may still apply as
valuable options in patients who are surgical candi-
dates (11,21) (Central Illustration).
While restenosis of the wound-related artery may
result in the failure to heal an ischemic wound,
numerous other CLI-related and therapeutic-speciﬁc
variables challenge the primary role of sustained pri-
mary patency on limb preservation and are con-
founders in interpreting the results of a clinical trial.
Factors such as the status of pedal circulation,
wound infection/location, and the frequency/quality
of podiatric surveillance programs and wound care
may either positively compensate for restenosis or
negatively impact the persistent patency. Although
TABLE 6 RC Subgroup Analysis (ITT Population)
Primary safety endpoint IA-DEB PTA
RC 4 12.12 (4/33) 20.0 (4/20)
RC 5 19.0 (37/195) 14.8 (13/88)
RC 6 0.0 (0/4) 20.0 (1/5)
12-month all-cause mortality DEB PTA
RC 4 6.3 (2/32) 10.0 (2/20)
RC 5 11.0 (21/191) 8.2 (7/85)
RC 6 0.0 (0/4) 0.0 (0/5)
12-month major amputation DEB PTA
RC 4 0.0 (0/32) 0.0 (0/20)
RC 5 10.5 (20/191) 3.5 (3/85)
RC 6 0.0 (0/4) 20.0 (1/5)
Values are % (n/N).
RC ¼ Rutherford class; other abbreviations as in Table 1.
CENTRAL ILLUST
Shown are key angio
treatment groups at 1
PTA ¼ percutaneous
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1574the IN.PACT DEEP trial is the largest randomized CLI
trial to date, its cohort size may be insufﬁcient to
adequately reﬂect the breadth and heterogeneity of
the CLI disease spectrum (22,23). More speciﬁcally, the
trial was not powered to assessmajor amputation as an
endpoint.
The ﬁrst reported use of IA-DEB for infrapopliteal
revascularization originated from a single-center,
retrospective, self-adjudicated 104-patient registry
(13). Long and complex lesions (mean 17.6 cm, >60%
total occlusions) were treated within a mixed popu-
lation of CLI and severe claudicants resulting in a
3-month angiographic restenosis rate of 27.4% and aRATION Selected Subgroup Analyses
graphic and clinical endpoint differences between the control and
2months. AFS¼ amputation-free survival; DEB¼drug-elutingballoon;
transluminal angioplasty; TLR ¼ target lesion revascularization.12-month TLR rate of 17.3%. These initial IN.PACT
Amphirion restenosis and TLR rates results were a
considerable improvement when compared with the
68.8% 3-month restenosis and 50% 1-year TLR rates
from a historical PTA cohort of similar baseline char-
acteristics (16). Liistro et al. (14), in a single-center,
randomized, self-adjudicated 132-patient trial, also
reported signiﬁcantly lower 12-month restenosis and
occlusion rates of 27% versus 74% (p < 0.001) and 17%
versus 55% (p < 0.001) in IA-DEB compared to PTA,
respectively. The investigators reported reinterven-
tion rates of 18% versus 43% (p ¼ 0.002) in a diabetic
CLI population with a mean lesion length of 13 cm and
80% occlusive disease (14). The extraordinarily high
limb preservation rate reported by Liistro et al., with
only 1 major amputation in the PTA arm (despite
higher rates of restenosis and reintervention at
1 year), may reﬂect optimal revascularization out-
comes combined with a meticulous wound surveil-
lance program with twice weekly ofﬁce visits for the
ﬁrst 2 months, ofﬁce visits once a week for the third
month, and then every 2 weeks thereafter. Notably,
no standardized protocol to guide wound manage-
ment was mandated in the IN.PACT DEEP trial
participating centers. Wound management was
administered according to the individual sites’
standard of care. As previously noted, 23.5% of pa-
tients in the IA-DEB arm and 29.4% in the PTA
arm received self-administered wound care. The
contradictory conclusions of the IN.PACT DEEP trial
compared to these 2 studies raise questions as to
their methodologies and validity. It is not uncom-
mon for single-center trials to show larger treatment
effects or even report opposite outcomes compared
to large, multicenter trials (23–27). Besides un-
avoidable differences in patient populations across
trials, systematic (and unmeasured) errors are
typical of single-center trials, which may result in
superior outcomes that may not be generalized to
other, less expert practitioners from lower-volume
practice settings.
The reason for the IN.PACT DEEP trial DEB arm’s
failure to meet its efﬁcacy endpoint and to report a
safety concern remains a point of conjecture. It can be
hypothesized that potential disease, device, and/or
procedural speciﬁc factors might have contributed to
the observed lack of drug treatment effect. The
observed 2.4-fold higher major amputation rate in the
study arm remains the most perplexing data to inter-
pret. It can be speculated that a wide array of factors
may contribute to the decision to perform a major
amputation, especially when an accepted and stan-
dardized deﬁnition of “planned major amputation”
was not implemented in the trial. Nevertheless, the
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: CLI, which
includes ischemic lower extremity rest pain, nonhealing ischemic
ulcers or gangrene, is the most severe manifestation of PAD and
is associated with a high risk of tissue loss, amputation, and
cardiovascular mortality. Revascularization by PTA is associated
with freedom from major amputation in a high proportion of
cases selected on the basis of angiographic pathoanatomy.
COMPETENCY IN PATIENT CARE: In patients with PAD who
develop CLI, angiographic assessment of percutaneous revascu-
larization by PTA should be considered to reduce the risk of
limb loss.
TRANSLATIONAL OUTLOOK 1: Longer-term follow-up of
patients undergoing PTA will more accurately characterize the
durability of percutaneous revascularization in patients with CLI.
TRANSLATIONAL OUTLOOK 2: Additional research is needed
to deﬁne the impact of speciﬁc balloon materials, coatings, drug
concentrations, and other methodological aspects of PTA on
intimal hyperplasia and clinical outcomes when employed in
various vascular territories.
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for the observed lack of efﬁcacy, including the differ-
ences in coating methods and balloon materials be-
tween the IA-DEB and the other DEBs in the IN.PACT
product line indicated for femoropopliteal lesions. In
this regard, the negative IN.PACT DEEP study results
are contrary to multicenter randomized and single-
arm studies (28,29) that have consistently supported
the safety and efﬁcacy of IN.PACT DEB for femo-
ropopliteal applications. It is worth noting that the
IN.PACTDEEP trial results only apply to the speciﬁc IA-
DEB study device for BTK revascularization. Positive
results on the use of IN.PACT and other DEB technol-
ogies have been consistently reported for the femo-
ropopliteal vascular territory, which may likely derive
from known differences in the severity of vascular
disease and DEB technologies (28,30,31).
STUDY LIMITATIONS. In the IN.PACT DEEP trial,
operators could not be blinded to the assigned treat-
ment. Moreover, the study protocol did not guide or
provide standards for decision-making involving
amputation and for the intensity of wound care sur-
veillance and care. Additionally, the low angiographic
and wound imaging compliance may have limited
the full assessment of this therapy. The subgroup
analyses have not explained the divergence of IA-DEB
efﬁcacy and safety results compared to prior studies.
Overall, these data reﬂect the challenges of CLI
research trials.
CONCLUSIONS
This ﬁrst multicenter, independently-adjudicated,
randomized, controlled trial of DEB versus PTA in
CLI patients with infrapopliteal disease demonstrated
that IA-DEB did not provide a signiﬁcant reduction in
either LLL or CD-TLR revascularization compared to
PTA. IA-DEB was associated with a trend toward anincreased rate of major amputations through 1 year
post-procedure.
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